(VIANEWS) – SEADRILL (SDRL.OL), X-FAB (XFAB.PA), VISTIN PHARMA (VISTN.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SEADRILL (SDRL.OL)
47.3% sales growth and 8.93% return on equity
Seadrill Limited provides offshore contract drilling services to the oil and gas industry worldwide. It operates in three segments: Harsh Environment, Floaters, and Jack-ups Rigs. The company owns and operates drill ships, semi-submersible rigs, and jack-up rigs for operations in shallow and ultra-deep-water in benign and harsh environments. It serves oil super-majors, state-owned national oil companies, and independent oil and gas companies. Seadrill Limited was formerly known as Seadrill 2021 Limited. The company was incorporated in 2005 and is headquartered in Hamilton, Bermuda.
Earnings Per Share
As for profitability, SEADRILL has a trailing twelve months EPS of kr624.22.
PE Ratio
SEADRILL has a trailing twelve months price to earnings ratio of 0.74. Meaning, the purchaser of the share is investing kr0.74 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.93%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 237.5% and a drop 30.5% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SEADRILL’s EBITDA is 224.29.
More news about SEADRILL.
2. X-FAB (XFAB.PA)
23.3% sales growth and 19.58% return on equity
X-FAB Silicon Foundries SE operates as an analog/mixed-signal semiconductor technology foundry. The company manufactures silicon wafers for automotive, industrial, consumer, medical, and mobile communications, and other applications; and analog/mixed-signal integrated circuits, sensors, and micro-electro-mechanical systems. It also provides manufacturing and design support services for customers that design analog/mixed-signal integrated circuits and other semiconductor devices, as well as engineering and prototyping, outsourcing, technical, and design support services. The company serves integrated device manufacturers, original equipment manufacturers, and fabless semiconductor companies. It operates in Belgium, Germany, the United Kingdom, Austria, France, Switzerland, Denmark, Sweden, Finland, Netherlands, Ireland, Singapore, China, Japan, Thailand, Malaysia, Korea, Taiwan, Hong Kong, New Zealand, the United States, and internationally. The company was founded in 1992 and is based in Tessenderlo, Belgium.
Earnings Per Share
As for profitability, X-FAB has a trailing twelve months EPS of €1.14.
PE Ratio
X-FAB has a trailing twelve months price to earnings ratio of 9.06. Meaning, the purchaser of the share is investing €9.06 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.58%.
Yearly Top and Bottom Value
X-FAB’s stock is valued at €10.33 at 06:20 EST, way below its 52-week high of €11.62 and way higher than its 52-week low of €5.21.
Earnings Before Interest, Taxes, Depreciation, and Amortization
X-FAB’s EBITDA is 17.73.
More news about X-FAB.
3. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 16.03% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23.5. Meaning, the purchaser of the share is investing kr23.5 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA’s EBITDA is 2.44.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the present quarter and 6.6% for the next.
More news about VISTIN PHARMA.
4. AXACTOR (ACR.OL)
5.2% sales growth and 9.72% return on equity
Axactor ASA, through its subsidiaries, operates as a debt management and collection company in Sweden, Finland, Germany, Italy, Norway, and Spain. It operates through two segments: Non-performing Loans and Third-Party Collection. The Non-performing Loans segment invests in portfolios of non-performing loans collected through amicable or legal proceedings. The Third-Party Collection segment provides debt collection services on behalf of third-party clients, which applies amicable and legal proceedings to collect the non-performing loans. This segment is also involved in helping creditors to prepare documentation for future legal proceedings against debtors; and handling of invoices between the invoice date and the default date and sending out reminders. Axactor ASA was incorporated in 1982 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, AXACTOR has a trailing twelve months EPS of kr1.49.
PE Ratio
AXACTOR has a trailing twelve months price to earnings ratio of 3.34. Meaning, the purchaser of the share is investing kr3.34 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.72%.
More news about AXACTOR.
